MedTrace Logo

Prucalopride and Cognition in Recovered Depression

NCT05220228 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-02-09

No results posted yet for this study

Summary

The current study has two aims:

1. To test the effect of 5-HT4 receptor agonism on cognition (including memory, attention and cognitive control) in individuals with previous history of depression.
2. To explore if prucalopride has an effect on emotional processing biases consistent with its effects on serotonin.

Conditions

  • Depression in Remission

Interventions

DRUG

Prucalopride

1mg prucalopride x 2d, 2mg prucalopride x 5-8d

DRUG

Placebo

Lactose / sucrose placebo

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Angharad de Cates, MRCPsych · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2023-11-13
Completion
2023-11-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05220228 on ClinicalTrials.gov